no, i don't remember that. the big tech movers, apple and amazon both under pressure we'll dig through results and comments from tim cook and jeff bezos. boeing returning the funding the bond offering is straight ahead. friday, may 1. "squawk box" begins right now. good morning, everybody. welcome to "squawk box" here on cnbc i'm becky quick along with joe kernen and andrew ross sorkin. let's get right to the markets it had been a banner april for stocks s&p and the dow closing out the best month in 33 years, the nasdaq the best month in 20 years. let's put this in context.

it took a tumble in less than six weeks and then rebounded 36% of the lows from april yesterday. the s&p down 34% from february 19 to march 23, less than five weeks. crazy to think about how quickly that fall came then we were back up 30% off the low for april. joe? >> if you used april then i could get to 82 years i don't think sorkin was listening to me. >> i was >> i said, no, i don't remember. you are always saying maybe -- i wasn't around for that here is my proposition for you, andrew sell in may is a common expression >> go away >> i've never felt more like selling in may than i do right now. i have to be honest. >> it is not just you. look at the dow this morning down 454 points.

>> just to test whether this kind of thing works. it would be impossible for me to go long with money what was he, 163 or something. i saw another guy say it is going to be so hard over the next year that we are looking at another 40% drop others that say the average recession that the market doesn't bottom for 11 months although jim paulson is saying everything is much shorter i think it is impossible to think about owning stocks right now. i will bet you the s&p is higher the end of may 31 than lower based on where the futures indicate >> right because -- >> right >> the wisdom now is that it is all going to go down >> i don't think i'm going to be right. i'm going to owe you

>> back up you don't think it is sell in may and go away. >> i do. but i feel that too strongly by that measure. >> sell in may and go away means you go away for the whole summer >> forget the expression what do you think happens in the next month i think the markets moved all the way back to what seems looic -- like a normal level. >> you think we'll be lower in may? >> i do but i'm going to take the lower. will you take that okay let's make that worth our while. ly -- i will buy you a box of doughnuts if we go lower you buy me a box of tacos if we are, say, above 2850 >> i don't know where we are

going to be. >> it is a box of tacos. >> you would eat take out a month from now you think it is going to be safe >> i eat take out now. i went to chipolte last week. >> again, glad we are not sitting by each other. >> the hardest trend to make is -- >> fighting conventional wisdom. >> can you think why this market would be above 2,900 end of may trying to reopen the states. >> it is a learning experience i'm giving you that opportunity to buy you doughnuts you'll be back here probably you can think about it >> take the bet.

>> how about i buy you a hypo allergenic bond. >> two bets. >> we can do two >> i don't think, i don't like to say this, i don't think either myself or becky will be sitting there in a month >> that will be even more interesting. that will mean we don't get back to work. nobody is rebounding in a v way. then you should take my bet and say we are going to be lower on the s&p. >> doughnuts versus tacos. >> doughnuts for me. tacos for you. >> a big box like 12 of them 12 doughnuts or 12 taco bell tacos. what do you want becky

>> i'm going to take andrew's side on this it is tough unless there is some miraculous recovery. >> that's my point i want to take your side too i can't imagine. >> i want to take your side. i would love for us to be up at those levels >> plus we have sell in may going. anyway >> one thing i did want to point out is that we fell so far so fast, look at those numbers, six weeks for the dow less than 38%. five weeks for the s&p down 48%. that is phenomenal it was a slow bleed in the past. this is where markets came to the conclusion quickly thank you to petter fer for rung those numbers this morning showing how huge those drops were we can't look at march's numbers.

we have to start from the market highs and how quickly we came down from there. you are talking about massive gains where we had a shock to the system >> we want to tell you about a number of important interviews the ceo of cargill who doesn't normally do television interviews talking about the strain and shell ceo talking about the strain on that company gilead's ceo to talk about the drug remdesivir and ceo of moderna who are working on those vaccines that is the big question that big news could totally change any of this and make what joe says right >> normally, i would this is an important quarter

like the industrial company, they are all important those are the ones i want to hear from today. cargill, you know why. >> because of the food >> oil that is the hugest question going. the dow component and oil to find out what is going on too with chevron >> we have a lot of corporate news some of this may be with the futures this morning let's catch up on three of the digest stories of the day, apple, amazon and boeing mike stoantoli joins us now. apple saying they see weak iphone sales tim cook pulling guidance, comments says he has great confidence in the long term of the business but in the short term, it is hard to see how the windshield, he says, to know

what the next 60 days look like. mike what did you take away from the numbers or of his tone >> right the tone is one of essentially not pretending that the company has a firmer grasp of what the next couple of quarters looks like than the rest of the countries has. but continuing to perform in a way that is very steady. not fast growth. it is holding its form the buy back, probably the middle of the road but less than they could have done in the past the stock, these huge tech stocks they don't really owe you anything they've outperformed in the nearly 40-year outcome, let's not look at today's movement and

say it is the market's verdict that something is wrong. but a very legitimate question it is a wait and see situation you have to wait and see if apple can hold on these situations it is getting a lot of credit for being this financially unassailable business at a time when we don't know what growth looks like >> let's also talk about amazon this morning seeing a surge in online sales and cloud business as people are stuck at home. the outlook slamming the stock this morning the company saying, this is one of the great lines i've seen if you are a share holdholder o amazon, you may want to take a seat they plan to spend $4 billion on

virus response more covid-19 tests for workers, shoring up delivery network, higher wages and more ppe. i think this will solidify their dominance in the space some investors not as happy about it, which i'm confused by. mike >> everything going on right now is going to enhance amazon's position in terms of the longer term trend the demand really can't keep up with it. the difference this time is that investors, they are used to jeff bezos saying forget short-term profits, we are going to invest. this is a little different in that it is not really spending $4 billion for some payoff down the road by creating a new business or marketing or

building infrastructure. it is really to deal with the conditions right now it is kind of lower or zero negative margin spending it doesn't change the long-term story. there is a difference and now we are saying we are recovering where we are right now >> i'm going to take the other side i don't see it that way. i think if amazon can deliver or can deliver all of the goods it can, it not only buys itself the market share, you think it would buy more you can do the things and do it profitably and do it without political pressure because they are not providing the ppe and the things you would want them to do that the danger and the risk to business is even higher. i look at it as an investment that has more than a zero margin return, if that makes sense.

>> it is still defensive and reactive it is absolutely necessary for the franchise and i'm sure that's the way wall street will view it over time. in the very short time, let's remember, amazon was at an all-time high. it was up 12%. we are giving back what we built up in this rally, which did get a little stretch and overheated a couple of days ago >> why isn't it back to the future this is what we learned from them it is back to what we do take my word for it. you are worried about coronavirus impact, ppe and things like that right? >> that's what you are spending it on, joe >> i'm saying, it is back to the revenue model where you grow market share and you may not be as profitable as you like.

look where it is i remember people shorting it to 1,000. remember the clowns that shorted it up to 1,000 let's talk boeing. the company raised $25 billion in a bond sale the blowout number that says will keep them from taking government aid you got some owe pinions on this >> no direct government bailout money. it was affirmed and downgraded the price they are paying for the debt is a little bit lower

there is a little bit of play there. clearly boeing feeling like it is worth it and where it will be for years to come. it changes the profile and now looks like it is a pretty indebited company. that's why it was viewed as well worth doing at this point. huge demand and blue chip view right now however you slice it >> you want in on this bet nothing to do with draft kings and not having anything to bet on i'm not jonesing for action. >> lie >> it is a psychological hedge on your part you want some reward down the way. >> that's the opposite i wouldn't mind losing this bet.

this gives me something i look forward to either way. >> you've watched the market for many, many years >> i would think i would have to have my head examined to go along. many times when it is all said and done so what do you want if you win a year's subscription to barrons or something >> i think i'm still on the list there. >> you still get that for free that's a huge perk you don't want in on this. you won't take the over or the under? >> no. i don't want in on a 30-day window by the way, sell in may is really about six months of the year >> you are right i have been looking. naz car is starting. who should i take in the first race do you like this jimmy johnson guy. >> my question is phil or tiger?

>> you should be in the option business we are not allowed we are allowed to sell calls or i think we are on a stock, we are allowed to own which has an enviern -- universe of one. we'll talk about what is next in oil after the break. 7:00 a.m., chevron ceo mike wirth will join us we'll be right back. i'm 53. but in my mind i'm still 35. that's why i take osteo bi-flex, to keep me moving the way i was made to. it nourishes and strengthens my joints for the long term. osteo bi-flex. find our coupon in sunday's paper.

seeing the break in the clouds before anyone else. together, we'll weather this storm.

and... l(music fades in). hey! -hi! ♪ ♪ ♪ ♪

crude rallied yesterday after several producers said they would cut outlook the outlook remains cloudy even as opec's new deal is scheduled to go ahead. let's welcome the managing director for april, you use the word trough do you think it will last two months or do you think that's the lowest it gets >> i'm not sure it is the lowest it gets. it is about as low as it can get without disease getting worse.

there are tons of global demand just disappearing is pretty bad. we are at the reopening phase in the world's largest oil consuming economy. if the 30 states that are reopening now, if they really get back to transportation as usual, we are talking head room of about 2.5 million a day upside to the loss of about 30 million barrels. s at the same time on the supply side, you are looking at 10 to 12 million a day depending on how much will shut down in the near future. coming in close to a half of the supply this isn't necessarily the end of the trough.

the v shape we saw and to have a lot of other things. it is not going to and will have the delivery it goes to the point that the new normal there is at a very low and implies a scarey supply and demand dynamic for the oil market that no one was expecting six months ago >> when you look at the lower price of oil, that really underperforms all of the expectations breaking into the 40s. you ask where are we right now if i say, the good news of the

story is that we have added a few willing owe bricks to the stack. that means inventories are still expanding. not good news yet. when you ask where are things going, it happens fast at the end. it starts gradually and then suddenly when inventories rebalance, they are a long way off we are saying 0 of 50 states reopening is no small thing if it goes well if it goes poorly, it is really bad news >> thank you thank you for being with us. >> thanks for having me. >> you're welcome. a lot more this morning. another retailer in jeopardy another big name that may soon file for bankruptcy protection as we head to the break, here are some images of the impact of the pandemic yesterday across

america. flexshares may look simple on the outside. but inside every etf... there are untold hours of careful construction... infinite "what ifs?" and contingency plans. creating funds that help target gaps in client portfolios. tap untapped potential. and strengthen confidence in you. flexshares. powered by over a century of investment expertise before investing consider the fund's investment objectives, risks, charges and expenses. go to flexshares.com for a prospectus containing this information. read it carefully.

for a prospectus containing this information. here's the thing about managing for your business.s when you've got public clouds, and private clouds, and hybrid clouds- things can get a bit cloudy for you. but now, there's the dell technologies cloud, powered by vmware. a single hub for a consistent operating experience across all your clouds. that should clear things up. since 1926, nationwide we've been there in person, during trying times. today, being on your side means staying home... "nationwide office of customer advocacy." ...but we can still support you and the heroes who are with you. we're giving refunds on auto insurance premiums, assisting customers with financial hardships, and our foundation is contributing millions of dollars to charities helping with covid-19 relief. keeping our promise to be on your side.

welcome back to "squawk box. it is time for the executive edge sad for me because i wear this all the time j. crew preparing for bankruptcy as soon as this weekend. they are working on $400 million in financing the retailer has been struggling under a heavy debt load and sales challenged by the covid-19 outbreak of course there were problems long before covid-19 for the company. all of it magnified in a world where people aren't going to the stores and the stores themselves are closed >> you wonder how much of this with the retailers go into

bankruptcy restructure and are able to come out stronger versus able to look at a different form and shut down all together >> that doesn't seem like your style, sorkin. it is low end, isn't it? >> i would say the past couple of years, when mickey were running the place. some of the goods were really high end i own a couple of their suits. i love their stuff becky, are you a j. crew wearer? >> it depends. everything goes through trends >> i have a go-to shirt that always looks good. it is rare that i need to look good when i go out it is friday, so i'm going to do one more thing i know there is a pandemic >> i want to do something. >> are you still into

lululemons are you doing that every day at home you come in here dressed to the nines. >> those abc pants you have, i own a pair i used to use for traveling, now i use for whatever >> are you wearing them today? >> i am wearing them today i have a lot of ag jeans or chinos, five-pocket pants whatever they are called >> you never do that here. you have to go and impress people at lunch typically. >> absolutely. it is the way i work. >> it is not you he's trying to impress. don't forget the berkshire hathaway shareholder meeting is happening on saturday. you can email questions to

berkshirequestions @cnbc.com make sure you tune in on 6:00 a.m. monday morning to get at in depth look at the meeting like you've never seen before they are looking at taking questions for a couple of hours, i think. this is what i wanted to mention, today is may 1, the 25th anniversary for john lefante our audio guy. he's been with the company for 25 years we want to give a shout out to john he's been putting up with me for a long time but joe even longer. he did tell me this morning, one of the big reasons he is here is because of you >> he mentioned that to me i said why do we go back and forth. if i got you to keep this job 25 years ago, why are you such a [ bleep ] [ bleep ].

>> he saves your button a regular basis. >> he comes up with sound effects and music or something in the old days, he used to throw in austin powers or a yeah baby >> 25 years, that is great he had a family. he comes in and had a great career still has a great career >> he's been putting up with you longer than penelope has >> he thanked me it is a longer relationship than with penelope. >> he did say you are the reason he has stuck around. >> i had to stick up to him with the bosses like something was wrong with this guy. i think it is brigette she's still here >> she is. >> where was brigette 25 years

ago? that went like, snap >> like the 82 years >> all right >> when we come back, we'll talk about the slide in apple and amazon cara swisher is next plus the ceo of cargil, plus ceos of gilead and moderna that's next. business as usual. that's why working together is more important than ever. at&t is committed to keeping you connected. so you can keep your patients cared for. your customers served. your students inspired. and your employees closer than ever. our network is resilient. our people are strong. our job is to keep your business connected . it's what we've always done. it's what we'll always do.

good morning welcome back to "squawk box. take a look at u.s. equity futures. we are in the red. the dow will open down about 421 points the s&p down about 55 points and the nasdaq down about 208

points apple and amazon reporting yesterday. the main focus on the calls was the ongoing coronavirus pandemic joining us now for her big tech take aways kara swisher, just announced is launching a podcast with the new york times, also a cnbc distribucontributor. and wherever she is, it must be sunny. >> you are lucky i'm here, andrew >> jeff bezos says to his shareholders that, you may want to take a seat the company plans to take the $4 billion it was going to make and reinvest it in the business mostly in the form of really

trying to make the pandemic better to the extent you can secure ppes and testing for employees. a big deal there the question is, how should investors feel about that, how should the public feel about that >> welcome to jeff bezos you and i have covered him for a long time. he thinks this is the best thing. his weakness is dealing with workers. that is something that has gone on for a while before this and may go on after this they have to consider the surge in revenue i imagine that bezos that is apparently quite running the company after having step add way. he's saying, we are going to take advantage of the gains we are getting during the crisis. of all the companies, amazon is the one, i hate to say it, will benefit the most and get people

on to prime and everything else. this is what he does he doesn't think much about returning money to investors as apple does >> you said you hate to say this because you don't love the idea of market dominance. >> no. who does >> i wonder if there will be a shifting perception of amazon and the tech backlash given the role some of these companies like amazon are playing during the crisis does that change the political winds at all >> i wrote about it today. i still don't like it. it wasn't right before this happened and isn't right after i don't know what change we have to allow one or two companies dominate and not allow as much innovation you saw last week around amazon, a lot of noise out of washington and bills about consolidation and everything else.

the combination of this financial mite that companies have that they have the ability to withstand this as everybody comes out and is limping, they'll be running down the highway. you have to think about things before this and not necessarily change them going forward. >> can i push back on one thing, i typically don't like dominance either but, a, they are providing a service and a service most other companies are incapable of providing in part because they don't have the size and scale. in a situation like this, you have to look to the giant. even walmart isn't as robust and have the same type of ability to

get to people. it made me actually try to rethink some of these issues >> rethink what? that you want one company to dominate everything and when everything is open, there aren't enough to continue i'm a competition person amazon has been astonishing innovative compared to other companies. just like we don't like microsoft dominating or google dominating search. go back to at&t, standard oil, it is not good for one oil company to own everything. it doesn't change because of the pandemic the reason they are really good is because they are dominating post this when we are trying to recover. the inclination will be to let them be giant. let them all be giant. the implications down the road are not good for innovative

startups definitely not for the marketplace and the creation of companies. i just don't see it. >> what is the swisher hot take on apple >> you know -- go ahead. >> no. go ahead >> i think it is maintenance >> i whaas going to ask you -- >> they are doing a good job but what amazon is doing is better china is looking better. services is looking better i just interviewed dallas about his new book, he called apple a company of confinement i don't necessarily agree. >> is there another company out there you think is being more innovative right now >> i think netflix talk about preparing for something and having the goods

when something happened. their products are great i just did an interview with ryan murphy who they did a big deal with. netflix to me is a fascinating company. >> final question, you have a great blur going on behind you, is that zoom blur or teams blur? >>s >> it is skype blur. it is just a blur. it is my closet. my cleaning closet next time i'll leave that on, it is beautiful >> kara, thank you for waking up early with us. look out for that column today we are moments away from a rare interview with the ceo of

cargill about the world's food supply remember, you can watch or listen to us any time on the cnbc app as we go to break, a look at some of the states that are reopening across america we'll be right back. every financial plan needs a cfp® professional --

confident financial plans, calming financial plans, complete financial plans. they're all possible with a cfp® professional. find yours at letsmakeaplan.org.

welcome back u.s. equity futures this hour are under some pressure. this is the first day of may we saw a very strong month of april. you saw a rebound better than 30% for the s&p and for the dow the biggest climb in the five or six weeks ahead of that. you are looking at the dow down about 437 points s&p down 57. when we come back, we'll have a rare interview with the ceo of cargill. we'll tell you what you can expect and what he sees happening as things potentially nt yback to normal or ifou wa to call it the new normal all of that to talk about coming up next.

welcome back, everybody. chevron out with its earnings. the company is talking about earning $1.93 a share. something like $240 million for up stroo upstream assets in the philippines. coming in better than expected

$31.5 billion versus the $29.38 billion estimated they are talking about how they are going to cut cap ex spending for 2020 even further. you may remember the company came out saying they were cutting the cap ex saying they are further increasing guidance down to $14 billion. they also say they estimate 2020 operating cost will be cut by a billion dollars. they are doing these extraordinary moves to try to make sure they defended dividend yield. yesterday was 5.6% based on the closing price yesterday. they told us at the time back on march 24 that they would try to defend the dividend. they are taking additional steps to do that today we will have michael wirth, the ceo of chevron joining us in about 15 minutes we'll talk to him about the extraordinary moves the company

is taking. in the meantime, a warning earlier this week from a major meat producer. tyson saying the food supply chain is broken. across the nation, meat packing plants have closed, fallen president trump also invoking the defense production act to secure meat production joining us to talk more about this is the ceo of one of north miracle america's largest food producer david cargill joins us we appreciate your time. great to see you. >> thanks for having me. good to see you too. >> let's talk about what's happening and what you're seeing you think the food supply chain is broken? >> i would characterize it differently. i think the food system is under strain but it's incredibly resilient. it's been well documented there are a number of meat producing plants around the country closed

due to illness we've been fortunate none of our plants are closed today. we had one plant closed for about probably 17 days it's back up and running that's the good news we've got another plant in dan that we expect to have back up and running on monday, but i think the food system is resilient. particularly the workers, the people in the plant on the front lines are very resilient and very courageous to be doing what they're doing to feed the country. >> do you think the president had to do what he had to do to keep these plants open >> i think every little bit helps. it allows prioritization for ppe to get to the plant workers, masks, testing equipment and it consolidates decision making authority. what you were seeing in meat packing plants around the country was local authorities wanting to intervene and wanting to protect their local

populations, which is very understandable it consolidates decision making authority and delegates it to the secretary of agriculture, and every little bit helps, yes. >> why there have been so many outbreaks at the plants? it wouldn't have been a place i would have thought of ahead of time can you understand nursing homes, hospitals, why are meat packing plants a place where we've seen so many infections? >> they have large employee populations. a typical shift at say a pork or beef or poultry packing plant might have 800 to 1,000 workers or more on a given shift they typically are close it oftentimes is challenging th to have six feet. that's one of the things to make sure that they have ppe, we've been putting shields on the line to give them more protection,

giving everybody masks the basic reason is if high population working in relatively close proximity to keep the production of meat going >> you know, we have all been trying to figure out when the economy is going to open up and what that new economy is going to look like will people go to restaurants, ordering as much from grocery stores you had interesting thoughts on what happens because the food that is produced for restaurants is very different. it follows different lines from the food that is produced for groceries for customer consumption and we've seen that kind of play out in toilet paper. there hasn't been enough to go around because so much used to be manufactured for schools or offices. that's different from the stuff you buy on the shelves what do you think is going to happen as we start to emerge >> well, for sure as you said there's been a shift from consumption of food and food service at restaurants, quick serve restaurants into retail. i went to my local grocery store and there was plenty in terms of

beef and meat, but there was no soup so i think you're going to see some spot shortages of different products in retail, but to your point, i also think that the food service industry is resilient. people are learning how to do either takeout or curbside pickup or home delivery and we are seeing some rebound in food service volumes. the point that you made, it's a different way to eat the food is prepared differently. but i suspect coming out of this, you'll unfortunately see a lot of small restaurants, small locally owned restaurants, one in minneapolis that has announced they will not be reopening. you'll see some restaurants that will never open back up again. >> as a result are you changing the way that you set up your production lines are you making more for the stuff that will go to the grocery store versus to retailers from here on out

>> we will have to do that we have reduced capacity dedicated making food for food service. we produce cooked and value added eggs for the food service industry we did take down capacity in a couple of those plants or several of them three or four weeks ago. again, the good news is we have a couple of those facilities that we have started to ramp up production i think restaurants, food service are getting used to the new way of consumption the new way of delivery. so are consumers so to my point about resilience, i think the country's resilient. i think the food system, the food supply is resilient we're already seeing signs of that >> david, how do you plan in terms of production on your lines when we're not entirely sure what's going to happen, no company is, that's why so many have removed guidance in any of these public companies what's been the biggest challenge to deal with that to figure out staffing, to figure out how much product you're

going to be dealing with and how you get that shipped >> becky, i think the most important thing is to focus on the safety, not only the physical safety but the emotional well-being of our employees. ultimately the bottleneck in the meat supply has been around having the employees, having the workers feeling confident, feeling safe and obviously being healthy. again, having the -- getting quickly to giving them ppe, to getting temperature testing at the front door when they're coming in, the facility that i mentioned that we had to close, we had to close because of one of the functions in quality assurance that it so happened that the people that were in that particular function, they were all ill with covid and had stopped coming into the plant. so i think it's not only a function of having the right people there, the people perf m performing all of the functions. the usda people are in the

facilities i had asked secretary purdue ensure that the inspectors were there. they've been there i think by focusing on the emotional and physical well-being of your employees and your plant workers, that's how you keep the system running. unfortunately it's been challenging with some of the facilities having to close as i mentioned, we're seeing them come back online again. >> david, want to thank you very much for your time today we really appreciate t. it's good to see you. >> good to see you, becky. thanks for having us on. >> take care >> andrew? okay great conversation two big hours ahead. coming up, another huge hour starting with chevron ceo mike wirth on the company's cuts to capital spending we'll talk about the price of oil. plus, important interviews with the ceos of gilead and u n'waa. yodot nt to miss it. we'll be back right after this

big numbers from big oil we heard from chevron. exxon mobil is next. we'll be speaking with michael wirth about what he is telling markets today. that is a first on cnbc interview. futures indicating a sharp drop in stocks after the best month in 33 years. a breakdown of what to watch is straight ahead. two biotech companies with hopes of beating covid-19. we will hear from the ceos of

moderna and gilead second hour of "squawk box" begins right now good morning and welcome back to "squawk box" right here on cnbc. i'm andrew ross sorkin along with becky quick and joe kernen. take a look at u.s. equity futures on this friday morning we are in the red. dow looks like it will come down about 450 points s&p 500 off 58 points and nasdaq looking to open down about 316 points, joe. i don't know about our bet. >> 2850. >> i'm worried that so many -- >> i'm giving you -- >> i'm so worried. >> i'm giving you a little bit of cushion, too, because i think the s&p is indicated 2847 so you're already winning you're already winning in terms of the theme -- no, honestly, andrew i'm getting a lot of people writing in on twitter.

i mentioned jesse livermore's book from the 1920s where he makes that point that it's just so easy to see what's right in front of your nose that usually doesn't work with -- and i don't know what's -- i'm telling you what i would feel i would sell in may. i don't see how things could fundamentally warrant being back where we were at 2950. i don't see how it's possible. >> i like the exercise, joe. i like the exercise -- >> see what happens. >> yeah. i mean, i hope that you're right. i don't know that i'd jump on board with you but i hope you're right. >> what do you want? >> you said you were going to get me a dog don't try to weasel out of it. >> a hypoallergenic dog. >> yeah. >> andrew gets a dozen donuts. you want the kind that are really degreesy from around here or do you want dunkin' >> dunkin' 12 glazed dunkin' donuts. >> i want a box o tacos.

>> i want taco bell. >> you guys have to eat the whole thing during the show, whoever wins. >> i've done that. i can do that. >> you need to stick around after we eat it. anyway, a couple of -- >> no. >> a couple of big tech moves this morning apple reported better than expected profit and revenue but due to the pandemic, it declined to provide sales guidance. that is the first time it's happened in 17 years amazon seeing a surge in online sales and in its cloud because as people remain stuck at home but it's the outlook that are hurting the shares this morning. down almost 6% to 2,335. the company plans to spend all of its second quarter profits, some $4 million. on its response to the covid-19 pandemic beck bring >> all right, joe. thank you. chevron just out with quarterly numbers. revenue came in quite a bit

better than expected the company did announce a number of big changes including a big cut in capital spending. joining us is chevron ceo michael wirth. thank you for being with us today. >> you're welcome, becky it's good to be with you today. >> i don't even know on the bottom line how that $1.93 a share matches up to the street's estimates of 68 cents. i know there were a bunch of missing pieces revenue came in $31.5 billion versus the $29.3 billion the street was looking for you are taking significant steps to saying you are going to cut cap-ex and protect the dividend. why is that? >> becky, first of all, our thoughts continue to be with those affected by this virus and also with all the workers out there on the front line keeping people safe and providing for, including those from our company and many, many others. we had a solid quarter in the first quarter, but the situation

certainly is difficult in our industry for everyone, so, look, we're in a different place than many others. we were prepared to execute. our financial priorities have not changed. the dividend remains strong and safe and we know what to do and we're doing it, and that includes taking some additional prudent actions to further reduce capital expenditures and operating expenditures in response to the environment we see. >> michael, obviously in april crude oil prices came under extreme pressure i've never seen anything like it have you ever seen anything like that >> no. that certainly was a very challenging month, as i think we really have seen demand in places we've never seen before and the market reflects that and supply has been slower to respond to that. so prices reflect the real

dramatic impact of the slowdown and in fact shutdown of economies around the world as we fight the virus. so praiicing responded very quickly. as we begin to see things move forward and economies begin to pick up again, demand will gradually return >> i mean, we're looking at the june contract for wti. trading above $18.80 and that is a long way back from where we saw the may contract as it was starting to expire and close out. what were you thinking as we watched the may contract go negative people were paying people to take oil from them what did that mean for you >> well, we know that because demand is off so much that production needs to find a place to be stored if it can't make its way into refineries, not into the marketplace in the financial markets these contracts close each month and there's an obligation to take

product if we hold a contract, and without a place to physically store the oil, i think you had some people who were caught in a position where they couldn't actually accept delivery and they had to get out of these positions and eventually ended up paying for that our company is a big player obviously in physical markets, not so much in the paper markets. so those two had become somewhat disconnected here with these unusual conditions sort of watch that very closely because the physical market can price off of the paper market. we're not actually a big play zwlerp certainly a never before seen state but it's supply is and demand in the marketplace today. >> you're one of several companies, i believe, that's leasing space in the nation's strategic petroleum reserve. why are you doing that what does that give you in terms of flexibility >> well, it certainly gives us some operational flexibility as

these markets try to find a bottom and recover, and producers are looking for places to temporarily store their oil normally the government buys oil to put into the reserve, and in this case because the money hasn't been appropriated they choose to lease space out to a number of players. as an operational manner, we have production, refining, marketing. we have storage capacity along the value chain and an opportunity here to take some storage for a period of time allows us the operational flexibility to manage the logistics in our business through this period. >> michael, the steps that you're taking today, including cutting capex by another $2 billiondown to $14 billion, is that something you're doing because you have to based on the moves we saw in the lastmonth, which all came after the first quarter ended or is that something you're taking in case

things get worse from here >> well, we were prepared. you know, the playbook to respond to a situation like this in our industry isn't really a secret what matters is how you execute. so we've already taken strong moves on capital spending announcing today another $2 billion reduction so that's 30% or $6 billion off of our original budget. we'll actually end the year at a spending rate that's about $8 billion below. so 40% reduction stock share buy backs of 5 billion per year we offered a billion this year and a billion next year. we've been able to close almost $2 billion of asset sales even in this environment. in a low price situation in a commodity business, revenues dropped much faster than costs adjust and so it's important to have a strong balance sheet and it's important to be able to take the moves and conserve cash

through this period of time. we came into this with the strongest balance sheet in our industry and have moved quickly and decisively to protect that balance sheet which allows us to protect the dividend to our shareholders. >> by cutting operational costs by a billion dollars, what does that mean in terms of jobs will that impact people who are on the job today or does that mean you won't be hiring people to do additional drilling that you may have planned before these changes took place >> well, in the short term what it means is we've obviously reduced travel we've reduced a lot of discretionary spending we have fewer activities and have constrained a lot of different activities so third party spending on suppliers is down before this began we had announced the intention to further improved returns and

become more of that. that work was important before we entered this time it's important how to be efficient. there is likely to be some impact to staffing levels and work force that was work that had begun even before the coronavirus. >> michael, the trump administration has said that chevron has to wind down its operations in venezuela by the end of december. i think you're the last ones operating from there from this country at least what does that mean for you? >> venezuela has been under sanctions now for sometime, th country, and certainly individuals. we have been in venezuela for the better part of the last 100 years. the treasury department has issued repeated 90 day licenses that allow us to remain in the country. we don't actually operate any assets in venezuela.

we're a partner in two operations operate the by a different company. we support it with engineering, maintenance and that type of activity and in the past had lifted crude oil in parts to fund the operations of these two ventures the licenses have gradually restrained the types of activities that we can do as a part ner in these ventures the most recent license runs longer than 90 days. it asks us to wind down certain additional activities that we've been previously allowed to do. it doesn't actually require us to reach it, it restricts activities for smaller things. so we intend to comply, obviously, with the requirements of the government, but we're not actually winding down or leaving the country. we're winding down certain

activities and still able to pay our people, support communities. it's very, very important in this and hopefully preserve it for businesses so we're prepared to go forward. >> michael, as a global company you have a pretty good idea how things are operating in different parts of the world we're kind of waiting to see what happens as our company opens up again potentially at least in some states to get back to business. what have you seen in terms of demand for the rest of the world? china's ahead of us, europe is ahead of us. i guess i just wonder, do you think we've seen the worst of it do you think it's going to get easier monitoring shipments of oil from around the globe what's your best take? >> yeah. certainly this quarter looks like in our industry we're seeing a bottom, and, you know, demand for -- >> this quarter being second quarter. >> this quarter being second

quarter, that's correct. first quarter we were on a bit of a downward trajectory certainly accelerating as we went through march i think in april and may we're finding a bottom in demand jet demand for aviation use is off 75 to 80%. some places deeper gasoline demand, plus or minus 50% off. diesel, 25% off. those numbers are relatively consistent in most regions around the world what we're seeing hear in the last few days and call it a week, week and a half, is things seemed to have bottomed and leveled. in certain areas we've seen a bit of an uptick off of these very low levels. i think we're still in a place where governments are trying to understand how to allow their economies to resume. everybody is at a different place. plus or minus, i think, through this quarter we're probably going to see things at a level

space and beginning to return. certainly the data would suggest we're beginning to see that, but it's going to be a very, very tough quarter. >> michael, thank you for your time we really appreciate t. thank you for coming on with us. >> becky, thank you. always good to be with you >> good to see you andrew when we return, we're going to talk to lynn forester derothschild. and we'll speak to the ceos of moderna and gilead. as we head to a break, let's get a check on the markets "squawk box" returns right after this there are times when our need to connect really matters. to keep customers and employees in the know. to keep business moving. comcast business is prepared for times like these. powered by the nation's largest gig-speed network. to help give you the speed, reliability, and security you need.

tools to manage your business from any device, anywhere. and a team of experts - here for you 24/7. we've always believed in the power of working together. that's why, when every connection counts... you can count on us.

featuring the emmy award-winning voice remote. access to your favorite apps, including netflix, prime video, youtube and hulu. all without changing passwords and inputs. the most 4k content and movies and shows on any screen. the best entertainment experience all in one place. so we're working 24/7 toected maintain a reliable network, to meet your growing internet needs. we're helping customers who are experiencing financial difficulties stay connected. we're increasing internet speeds for low income families in our internet essentials program. and delivering self-install kits to your door. nos comprometemos a mantenerte conectado. we're committed to keeping you connected. for more information on how you can stay connected, visit xfinity.com/prepare.

>> how is it supposed to work. >> they are catching up. to their community and to the planet davos was all about stakeholder capitalism and so we have a move among corporate that this is morning, however, from an investor's point of view, unless the metrics about how a company is taking care of its people and planet are standardized and

assurable, you really can't invest properly. you can't really be an employee who understands the difference between employee treatment at the different companies in the same industry and as a consumer you don't really know. so what i'm arguing for is let's get standardized metrics that are material and are not overly costly to companies because right now trying to do this on a voluntary basis, and we have great companies in this country who truly are taking care of their people and their planet, but they put out glossy reports and there's happy talk it's very difficult to sort out the best and create a real race to the top, not only on financial measures which are, of course, important, but also on these non-financial measures so i'm arguing that government should create a body to create

these metrics. they won't be perfect but they'll be something >> lynn, let me ask you this though in this environment given the challenges of the economy, and we talk to a lot of investors. is esg more important or less important, a lot of investors say it's more important or as important than ever. however, you then think about the balance sheet and you think of the deltas of the world who have committed to spend $100 million a year on climate and carbon offsets you think about microsoft and the plans that they have can we really expect companies in this environment to actually follow through with some of these proposals, not because they were disingenuous proposals but because the world has changed and made it that much more complicated and difficult if the real goal was to help employees, as you know, i want to help the climate, too, you have to start to think about where you're going to allocate

your resources. >> of course that's true and that decision is different for different companies in different industries it's different for tech than it is for retail, for instance. but the point is that we went into this with an inequality where the top 1/10 of 1% of americans own 23% of our wealth, that's 160,000 americans who own wealth that is the equivalent to 290 people in america. if we get out of this with people employed, that is not an environment that is safe for businesses so of course you have to make decisions and you have to be proportionate among all of your stakeholders, not only your employers but obviously also your shareholders.

if any board is not thinking about the risk of something like occupy wall street times 1,000, if we don't begin to give the public real true understanding that our best companies are the ones that are taking care of their workers and their customers and their planet, and thank god there are a lot of them that are doing it. >> andrew, did you ask about climate change and carbon offsets. i guess it is interchangeable to a lot in esg you just answered that entire question based on income and equality. >> the climate issue, i agree, joe, that is another one that is very important for the long term that is the one andrew asked you about. you are able to so fascile go back and forth with esg people, to me it just sounds like any of the virtues

signaling things -- it doesn't even matter which question that someone asks you, you go just as easily between climate change and income inequality. i don't know i just thought it was funny, he asked you specifically about carbon offsets and we came back that we're going to have occupy wall street. >> joe, i'll take it -- >> go ahead. >> i just didn't understand it i thought andrew was doing really well because i don't know how with oil down where it is right now and we just want people employed and we want people, you know, to be able to get a paycheck and we want our company to be competitive globally, so it's going to be hard to make that transition to much more extensive, renewable type energies at $20 oil it doesn't seem like the time -- i know all the climate people say a good crisis, this is the time to see what it would be like if everyone stayed home for

the climate. doesn't seem to be a time to think about that and we want to get people back to work and energy needs to be as cheap as it possibly can. >> okay. that's a short-term view, and in the long term we have to protect our planet and i do think we have to deal, frankly, with the inequality problem and the climate problem concurrently it's complicated and a lot of businesses that are in alter alternatives are some of the most innovative in the world and they are going to provide energy that is clean because it is an existential threat over the long term so we understand that. >> before we let you go, one question you talked about what may happen on the other side of this pandemic i'm curious how you think this is going to change business, dare i say capitalism, taxes, all of it in an environment

right now where clearly there are at least questions about whether there is a free market given the government has come to rescue not just here in the united states but around the world. you could argue this is corporate welfare at the moment. the question is, you know, how you think that changes the conversation after. >> i think it changes capitalism forever, just like leon cooper man said on your show last week. when government is called upon to protect on the down side, it has a right to regulate on the up side. i don't think it's a winning argument to use neoliberal arguments against regulation when we are putting trillions and trillions of public money into the private market. i think we have to reform capitalism, and it's the same thing that happened after the depression capitalism changed and it, therefore, saved

capitalism, but when we have the private sector getting trillions of dollars, it can expect government to regulate for those 290 people -- million people >> lynn, great op ed go out and read it thank you for joining us this morning. appreciate it very, very much. >> thank you >> thank you >> becky, over to you. >> andrew, thanks. when we come back, hopeful signs in the battle against the coronavirus. gilead's remdesivir drug showing hope this week the company is ramping up production and the ceo will be joining us take a look at the futures on this first trading day of may. april was a huge one for the markets. the s&p is pointing down 65. we'll be right back.

time now for today's aflac trivia question. what day did the dow first close above 25,000 x"onnun bcsqwkcn "ua bo cties w smaller bills. fifty dollars here. eighty dollars. a hundred dollars. i had good health insurance. why isn't this covered? well, then they started getting bigger. eight-hundred dollars. eighteen hundred dollars. i saved for this. but not that much. i'm glad i had aflac. they gave me money when i needed it most. that's why aflac is here, to help with the expenses health insurance doesn't cover. i love that aflac duck. aflac! get to know us at aflac.com

♪ ♪ ♪

don't forget the berkshire hathaway meeting is this saturday they can email questions to berkshirequestions @cnbc.com we'll be asking hours of questions to warren buffet and greg able. there will only be warren and greg on stage. that will stream on yahoo! live. we'll stream it at 6 a.m. monday morning. we'll get all of those questions and answers coming up. joe? >> look forward to that, becky coming up, exxon set to post quarterly results. the numbers in the analysis next and then two of the major players, two really some of the most major, first moderna's ceo. it's the coronavirus first moderna's ceo and the company's plan to ramp up

vaccine production and gilead's ceo daniel o'day on the remdesir stay tuned "squawk box" will be right back.

the two companies are teaming up to find a large scale cure for covid-19. it will be great to scale this up the way that you do it, platform, using messenger rna to generate an immune response has

a lot of advantages. it scales up quickly first tell us about the numbers you think that you could deliver you are talking about a billion doz doses with vaccine development with lanza. >> yes, good morning, joe. thank you for having me back i'm very pleased to announce this morning, if you think about it, we're trying to do three things we are trying to get a vaccine as fast as we can. it will be announced on monday of this week it's a phase 2 study with the

u.s.d.a. and start dosing as we get the green light. and the third thing is manufacturing. if you only can make a few million viles, it's not going to be helping the global public health issue we have we have a plan for messenger cells and we have said that these plans can do up to 100 million doses per year, and this is, of course, great but it's not enough we asked ourselves how can we do 10x. we have the best contract manufacturers in the world in the space lan zwas tza was the partner. it's 100 plus year company they have sites around the world in the u.s., switzerland and

singapore. many more countries. we're able to move very quickly. we have announced we're transferring the process to new hampshire in the u.s we're hoping to start making product as early as july. >> stephane, we want to make sure the vaccine has the desired effect and immunizes people. there are a lot of competition with this. we heard from oxford university, we're hearing from pfizer as well with your technology, it's kind of interesting and i look more closely at it. with an rafael nadal virus, you have a big advantage because you don't need 1,000 times the dose to get into the nucleus to have it expressed it's 1/1000. my question is do you put in the entire genome of the

coronavirus and then some of it is expressed into protein which is where you get the antigenic response, that's how it works. why is it that putting in the whole genome can create an actual virus -- why doesn't it actually cause you have coronavirus? why is it attenuated which is what we normally need to do. >> in the case, this is not attenuated what we do is we give the messenger rna that instructs only one protein, the spike protein. we do not give the entire genome we give you the instruction of that protein of a virus. the full thing but no more what it does when you inject it into a muscle, you have human cells with the messenger rna and the immune response being very powerful. >> i understand. that's very good it's a protein that is

essential. one of the -- i don't know how -- not that many made. very small genome. it's a protein essential for the coronavirus to work. >> yes. >> go ahead. >> sorry it's the protein that allows the virus to get into the cell so by being able to have an antibody that your immune system makes to bind to the virus, we anticipate that will prevent the disease. >> meg, this has worked in other rna viruses, i think there's a proof of efficacy, i think. it's been done before. you go ahead with stephane, but should we be highly hopeful this is effective, this vaccine, meg? >> well, it is a new technology and has never been brought to market before but moderna has showed in other viruses promising earlier results. stephane, i want to ask you more about the manufacturing you're

doing with lonza they are manufacturing in the u.s. and switzerland how important is it where the manufacturing is done to which countries will receive the supply what kinds of pressure are you getting for different governments around the world to be sure you can supply vaccine to them? >> yes, good morning, meg. as you can appreciate, every government is very worried for its health and economy we're working in collaboration with many governments around the world. phase one in the u.s we have manufacturing sites that moderna owns and controls in the central states up and running. new hampshire is going to be next in the u.s. we think it's the importance where many nodes of

manufacturing around the world where we can provide as many as we can locally in each geography. that's what the government's looking for. >> so you mentioned that lonza will be doing it in the u.s. and switzerla switzerland. are you planning on supplying this in asia >> our goal is to make it available around the world we intend to do as many cycles as makes sense we want to make sure not to do too many locations because of the know how and the race against this virus and so we will work very closely with the governments and lonza's management and manufacturing to get the best use of sites. >> reporter: tell us -- sorry, joe. >> no, go ahead, meg. >> reporter: stephane, i wanted to ask you about the phase 2 study you filed for approval to begin with the fda

you're ready to start dosing to get the green light. when are we going to get the results of phase 1 trying to do this on top of each other in an expedited time line. what have you seen about the phase 1 and when will we get to see the whole results? >> we are starting the phase 2 based on safety of phase 1 as we've communicated two weeks ago when we got it from barda, the phase one is fully enrolled. three different dose level 45 subjects in seattle fully enrolled what we announced two weeks ago now, we have added 6 new cohorts to phase 1 healthy adults, elderly, 70 and above. the same dose level tried in healthy adults 18 to 55 years old. so as you can see from that, it seems that the safety first data looks positive it's not a surprise to us.

as you know, meg, we have a platform we use the same chemical in all of the nine vaccines we have in clinical studies up to completed phase 2 in the past. so, one, we always want to be careful about safety, especially for vaccine that's unique for healthy people it has never been something we have worried about very careful on the efficacy side, like any vaccine, we should be able to roll out phase 1 to get very good indication of whether the vaccine will be likely to work we take blood from the volunteers in that study, analyze that blood to see if we can make neutralizing antibodies to bind to a virus to prevent rope pli case. that will be important and that should be out soon. >> thank you, meg and stephane we'll have gilead on i would ask you. you know the technology of pfizer, oxford and others.

do you think there's an advantage in efficacy or the ease of production for moderna's version? it's interesting to watch this race because it's a race to really try to save the world we wish all of you god speed do you think you have an advantage in both efficacy and manufacturing, stephane? >> yes like you, joe, i want many vaccines to get to the finish line no one company can help the entire planet. many of us need to get there i think it's extremely interesting. it mimics the virus without giving you the virus the scale is impressive. i think it's interesting technology. >> thank you, stephane we hope to see you soon. thank you, again, meg. we'll see you with gilead. becky? >> joe, exxon out with results the current quarter results on this company is not going to be as closely watched

they came in with a loss of 14 cents a share. street was looking for them to earn nothing, flat, flat, flat all the way across that loss of 14 cents include charges that total up to 67 cents for a non-cash valuation for lower commodity prices and asset impairments. if you strip that out, it's a gain of 53 cents again, i don't know where the street comes down on this or if that matters the bigger news coming out of the company today is they are cutting cap-ex by 33%. they are cutting their cash operating by 15% earlier in the week we learned that exxon would be maintaining its dividend of 87 cents a share. this is a playbook we heard it from chef rorch vroo michael wirth. andrew >> thanks, becky when we return, the ceo of gilead sciences is goi tjongo in us to talk all about it. stay tuned we're back after this.

gilead, maker of experimental coronavirus remdesivir it spent $50 million on remdesivir research and development focusing on making the drug accessible. joining us is daniel o'day and meg tirrell stays with us. mr. o'day, thank you for being with us this morning you've seen instances where the entire stock market surges based on news that comes out about this drug, remdesivir. the importance i don't think can be overstated. can you tell us what will happen this week why that is

significant? as you pointed out, it hit its primary end point and it did it on the shorter trial, which doubles the amount that you have ready to go. both of those things have been important? >> yeah, very important, joe first of all, thanks on behalf of all of the colleagues at gilead that have been working day and night, this is an important week for us to see the two study results. so there are basically two studies that were announced this week as a result of those, one was the gold standard placebo controlled trial from the nih that was part of our suite of studies to determine whether remdesivir would be effective for the covid-19 virus and the second is the study of five and ten days of dosing both read out positive what that means is remdesivir significantly reduces the

recovery time for patients, again in the hospitalized setting we're talking about, and then many patients in the hospital can benefit from a five to ten-day dosing course it's obviously a benefit for patients but also for the health care system because if you can free up hospital beds at this time, that's absolutely fundamental. we're just humbled and pleased by the results this week as a starting point for therapies in covid-19 >> as a starting point, and that's something that's been pointed out on our own, dr. scott gottleib has pointed it out. it's active against the virus. is it going to be similar in the view to what some of the other viruses that's been tested, whether it's sars, mers, even ebola where it did show activity but maybe an antibody drug in conjunction with it would actually be more powerful in dealing with the disease

do you expect it to be one arrow in an arsenal of therapeutics or much better than that? >> well, i mean, we're hopeful i think these are really significant results on their own, i would say we're not done yet we have trials that will read out in more moderate patients in may to determine whether we can have an impact even earlier in the disease coursefor hospitalized patients. as you say now, the nih and we were pivoting to know new clinical ideas in terms of anti virals being one way to treat this disease could it be supplemented and complimented by different mechanisms being used beside that we have a playbook in antivirals that shows that oftentimes combinations of medicines is exactly what one needs to take the next step in terms of treatments we're going to be focused on both of those things

expanding the use of remdesivir and through different formulations and looking at how remdesivir might be able to be complimented by other medicines. >> earlier might work since it's not attacking the problem of the late stage patients with the cytokine storm if it was given earlier, it might work better than what you've seen with some of the more -- the diseases that have already progressed more in people. >> well, that's right, joe i think, you know, it's -- you know, maybe it's a little bit of a surprise to us that this medicine also worked quite well late in the disease course as well >> right >> so, you know, many of these patients in the nih trial were on mechanical ventilation. maybe 30%. those are the most severe patients interestingly remdesivir had an effect

we've seen the totality of the data of course we'll see that data being broken out by subgroups in the coming weeks, i'm sure the point is, yes, one would think that it might also work even better earlier in the disease, but i think the surprise is that it also works late in the disease. i think that's something that is -- has a big impact for patients, of course, with so many hospitalized patients in such great need. >> meg >> reporter: thanks, joe hi, dan. you mentioned that two studies -- >> hi, meg. >> reporter: hi. there was of course the third one from china, the incomplete trial where they couldn't finish the enrollment because case numbers were declining the full report in the lancet this week. a lot of groups are focused on that even though the trials weren't finished and it wasn't a positive study one thing analysts show is that it doesn't appear the drug was effective in the viral load. how are you interpreting that

and putting them into the full context of what remdesivir has >> thanks, meg i know there has been some confusion out there. i hope i can clear it up a little bit frmpt our perspective, we see tremendous consistency across all of the data we've seen so far in remdesivir that has data from our compassionate use programs and data from the inconclusive china trial. if you like the validated data, the most important from two randomized trials this week which really trumps that other data earlier on. just to make sure we set the record straight on this as well.

wcould you use awq it was halfway recruited when the disease in china was contained great news for patients. the result of that is you have an inconclusive trial. you can't make interpretations for that trial when one looks into the trial, you saw some of the same trends that you saw in the nih trial. so you saw around an early but inconclusive 23% improvement in patients time to recovery, whereas, the nih we saw a validated statistical improvement of 38% i do think one has to turn their attention to the trials that did complete and that did have the full patient dose. now to your point on the antiviral component of this,

we're still -- there's still so much about this disease we're still learning and what's clear in some other work we've done with the nih, the sampling of the virus activity may not be the best predictor of clinical outcome. in other words, sampling, you know, the virus nose and nasal pharyngeal pathways may not be indicative of what's going on in the lungs. i think we have to learn about this disease and in any case the most important thing is are patients getting better? and patients are getting better with remdesivir in this hospitalized, very serious situation. that's what we're focused on and we're focused on building on that early convincing data >> right as you build on the data, you are also undertaking a massive effort to increase supply of this medicine, something you

began months ago even before knowing how well it worked in this disease very complex drug to manufacturing and takes a long time we understand that your scientists have already been able to shorten those time lines. there was a note from rbc out suggesting that by their modeling gilead will only be able to supply enough to cover u.s. patients with covid-19. how are you looking a the the ability to supply the globe with this drug and what kinds of pressures are you already feeling from governance? >> let me first of all acknowledge the tremendous work of the scientists at gilead. it's only been three months since we kind of became aware of this virus, and we immediately pivoted our attention to the clinical trial work and to the manufacturing supply work. completely understanding we didn't know if the medicine worked but if it did work, we would need a lot of supply

and so what our scientists did, actually, in the past three months is took, as you mentioned, a very exacting comprehensive chemical process that is 20 to 30 steps, much of it has to be done sequentially and not in parallel, they took it from a 12-month start to finish time and brought it down to a six-month start to finish time that has allowed us to have exponential growth because we took the actions already in january. so we are focused on making sure on a global basis that this medicine gets into the patients that need it and we're focused on how best to allocate the medicine, you know, in these days than how to convert that to an allocation where we have more supply. the supply we have in our hands, the 1.5 million viles of remdesivir which equates to around 100 to 200,000 patient

courses depending whether it's a 5 or 10-day treatment, we will completely donate. we didn't want anything to get in the way of it getting into the hands of the patient that donation is a global donation we will work with countries and health care systems around the world as they make this medicine available to their citizens based upon their regulatory requirements to do our best to make sure we can allocate that accordingly. then come up with the right plan for how we then move from these hundreds of thousands of treatment doses to millions of treatment doses. but this is a global pandemic. it's a global problem and we understand our responsibility here >> and i know you've said it's too early to say where you're thinking about pricing this after that initial donation. you told analysts on your conference call last night there's no playbook for this we've never seen anything like this in the history of our existence or lives on this

planet but you are investing up to $1 billion in the trials and your stock was downgraded by three different analysts based on the lack of visibility of revenue into remdesivir. how do you as the ceo of this huge publicly traded company trying to serve the world the first drug that works for the pandemic, how do you balance the pressures from wall street and providing this drug in a pandemic >> meg, you know, it's a very natural thing at gilead for us to be able to focus on access and affordability and making sure that patients in both the developed and developing world and finding creative ways to get this medicine to patients. if you look at the history of this country with hiv when they took different approaches to get the hiv medicine to the

developing world, those are the same lessons we'll put to work as we think about the right, sustainable model to make sure that we can both invest in the future manufacturing and the additional research that needs to go along with determining whether this medicine can get to different patients, perhaps different formulations that can allow us to go earlier into other parts of the world, easier we understand a responsibility both to patients and also to shareholders and we'll be balancing that it's early days, right i mean, it's been three days since we've gotten theclinical trial results. we need to digest those. we need to understand what patient poch populations this s going to serve we need to understand the regulatory processes around the world and where will this go and the patients treated with this those are very, very important inputs to determining the model that we will move going forward. so i can tell you we take our responsibility very serious towards patients and we

understand our responsibility as a company as well and to our shareholders we will deliver that answer and that information as we can process this information so we can find the best way forward, i assure you. >> daniel, as you know, the world looks at a drug like this. you saw how the stock market reacted the day that the report came out as a new sense of confidence, this idea that people will feel more comfortable hopefully in the future knowing that if they were to get this that they may be able to get protected or at least not have some of the dire consequences that we know so well about currently this hasn't been used in a hospital setting. you've also made this reference to other formulations, and i was hoping you could speak to that, whether this could ever be in a pill form. we've heard maybe it could be put in an inhaler form and how

quickly you think any of that kind of work can get done because to the extent this can be done outside of a hospital setting, that would be -- that would be a material game changer even beyond the game changer that you've created already. >> well, yeah, thank you we're really focused on making sure that the iv dose, which is the dose and mechanism by which the clinical trials ran out this week, that we scale that up and that we get that focused and out to patients in need. but at the same time the same way our scientists back in january started thinking about manufacturing and increasing that supply, we also started to think about, you know, should this be effective, what are other ways we might be able to deliver this medicine to patients it's still early days on that and we hope to have some information relatively soon, but because of the nature of this medicine, it's not appropriate

for a pill formulation because this is heavily metabolized in the liver which means that it's not suitable for an oral dosage form to get the levels in the body that you need to suppress the virus. however, looking at subcutaneous formulations, looking at potentially inhaled formulations to get it right to the source of the massive viral replication in the lungs is something that we're firmly focused on now. again, gilead scientists are some of the best in the world at taking, you know, chemistry processes and determining the best way to move those formulations along and then our medical doctors find the best way to treat those we should have more information on that shortly, but i want to make sure that doesn't distract from what our really primary focus is right now, which is to ramp up the supply for the intravenous medicine, get that in hospitals around the world, make that available for patients

that are in severe need at the tail end of their -- the process of the virus replication in their body >> hey, dan, i want to say thank you for taking your responsibility so severely and for agreeing to donate so much of this up front and making sure it will get to the right places. you are thinking about all of the right ways to do this. we've never seen something like this where the globe gets shut down, countries everywhere dealing with fallout from that and i just think this might be a little different than what we've seen at other times with hiv or any other disease that has been taken on before. i know you have manufacturing and supply chains in different places i wonder if you can explain where that is, where you need these components from and whether any country has moved to try to say you're going to help us first >> well, that's a really important point,and we've already begun that process and we need to continue it

that is -- we've learned lessons, by the way, you know, from other pan dem mix and outbreaks like with influenza, that it's extremely important to make sure that you have a very robust supply chain with a lot of duplication in it, meaning that we have to think about having a supply chain that's global, that provides end-to-end manufacturing in different parts of the world we're working, of course, with lots of partners on this this isn't something that gilead does on its own. we're grateful to have relationships with high quality manufacturers and chemical and pharmaceutical manufacturers around the world as well as other regular biopharma companies that have stepped up and reached out and asked how they can help. it's been so impressive to see how the bio and pharma companies have done to see if there's

anything they can do to help with this virus. i'm very proud to be working with people doing everything from treatments to vaccines and dropping everything to get there. this is critically important for us, and we are scaling up that global supply chain right now. it's exactly what we're going to need to be able to be successful to meet the demand of the patients around the world. >> dab yeniel, has any country e forward and put the screws to you saying, you have to deal with our country first and our people first >> we have a terrific relationship in the united states and i can only say the government officials have been bending over backwards from regulatory to supply to distribution here in the united states and around the world. i've been amazing at the outpouring of obviously interest but also support so the types of discussions i've

been having with individuals around the world are productive conversations, they're conversations saying how can we help how can we expand the supply chain in our part of the world and, you know, really focused on patients, which i think is important. those are the types of conversations i'm having these days >> daniel, just one quick follow-up given your -- that you're going to be donating this drug, at least in the beginning. what do you think should be the business model for all of the other drug companies out there that are working on these endeavo endeavors? >> well, i think that's exactly the question that we're asking ourselves. meg mentioned it before. i think there is no playbook for this situation that we're in today. i think this is the time for us all as an industry and especially gilead to do the right thing. the thing is to make sure we can

get effective medications to patients we have to transition to a sustainable model that allows us to manufacture this successfully, allows us to make sure we can continue the investments. the reason that we're so ready today is because of decades of investment i think that's really important to point out you know -- i mean, remdesivir's story started ten years ago. gilead's story starts decades ago in terms of antivirals this is not an issue of taking something off the chef, this is something where we had invested in the science behind emerging viruses, where we tested remdesivir in a variety of different viruses as they came along, and thankfully because of the broad antiviral nature of it, when we tested it against

the coronavirus family, sars and mers, we saw strong activity of this in the lab, and then we saw it with covid-19 so we were prepared for this but that preparation takes investment and it takes scientific know how and knowledge built up i do believe that a sustainable model for this is the reason we're prepared today at gilead as an industry and that's something we have to factor into as we think about how to get these medicines to patients around the globe. >> dan, as we've heard from a lot of your peer companies this week on the earnings conference calls, there is some hope from people in the trailer, it will reset your public image. as you talk about the new pricing models, do you think that there is going to be a resetting of how the industry thinks about pricing drugs in

general as you do aim to regain the public's trust >> well, let me say, meg, too, you know, i can't be more proud to work in this industry i feel privileged to have worked in an industry that has made such a difference to patients, that's literally really cured different forms of cancer in the case of gilead cured hepatitis c and hepatitis c is now taken care of. i recognize and acknowledge the fact that from a public sentiment standpoint we have work to continue to do it's a complex system around the globe in terms of access

making sure that patients don't feel the burden of the prescriptions is something that we at gilead are very focused on working with health care systems and governments to find ways for that to work i do believe this is a time to make sure we communicate the investment that we put into the these, the access programs and thoughtfully coming up with pricing models and reimbursement models that allow us to make sure these get in the hands of patients and also allow us to continue to invest in that type of research that produced remdesivir in the first place. >> daniel, it could have a positive effect in other ways, too, in that some of the misguided knee-jerk proposals we

have about maybreying back price controlled drugs because they aren't able to recop their investments. if they are able to recop it in a big way, maybe we would realize it's better to recoup drugs than in hospitals in terms of our health care needs we need the innovation, patent protection if companies spend $2 billion, we've protected that the trump administration seems to lose its way at times about what really makes sense but make sure we have innovation in the future >> well, i mean, joe, i just think it's absolutely fundamental. this industry has produced such

a benefit for patients but also for the health care system i mean, when you cure diseases when you turn diseases into chronic, manageable illnesses, you have a big impact upon the health care systems and, you know, i think that's -- that's at the core of what we do at gilead i mean, our ability to focus on transformational medicines, to focus on the science, to disproportionately invest in research and development is exactly what it's all about. yes, you know, we have work to do with policy makers around the globe to remind them of the nature of how that works the fact that 90% of everything that we take to human beings fails. you have to have a strong will and a lot of optimism to work in this industry and, again, i'm proud to work in it.

the model works. when you disproportionately invest and when you have patent protection for a limited period of time after you make those investments and i'm really proud of what gilead has done here with remdesivir. i'm just privileged to be a part of this. >> privileged to have you on and update us on all of this and hopefully we can see you with an update, you know, soon we'd like to hear whenever this moves along. the entire world is watching thank you. meg tirrell, thank you. >> thank you. >> you're very welcome let's get to dr. scott gottleib for a reaction to that interview. he's the former fda commissioner, cnbc contributor he serves on the boards of lumina and pfizer. were you able to hear the entire -- all of mr. o'day's comments, scott? >> most of it. >> most of it. okay do you have a top three things

that you were struck with in listening? >> this is an important event. we've said all along this drug is not a home run but it will be beneficial for a certain cohort of people with covid-19. they're going to have more supply than what we initially thought. they've been able to compress the time it toiks to manufacture this drug. it seems they've cut the time it takes to manufacture this drug almost in half from what it was originally they'll be able to stretch it and they may get a five day course versus ten day course it showed no measurable difference between five and ten days if they're able to dose this from five days to over 10, the nih study looked at ten days if you get it down to five days, that's going to effectively double the supply. heading down to the fall, you're

going to want to stretch the supply of this drug. this drug can be used for treatment. i suspect we're going to look at using it for prophylaxis for patients exposed to covid-19 maybe a limited duration it might help prevent the onset of symptoms, prevent people from contracting the virus. we'll start to use this potentially in different waste if it makes it to the market and i think it will in short order. >> be nice to have the inhaler. >> nebulizer. >> nebulizer, sorry. >> yeah, look, it's into the an on tow mall drug by any means. it's an intravenous drug right now. needs to be delivered in the hospital but, you know, that's not that much of an impediment because most cases you're going to be using this drug in patients who have more advanced covid-19 or patients with a higher risk of a bad outcome

they'll be hospitalized. we're a long way from having a tami flu outpatient drug, safe taken as a prophylaxis for people who are exposed as well as early treatment. we don't need that for the fall. if you couple remdesivir it will change the risk profile of this infection. >> we're going to get back becky wants to get back to talking about remdesivir i want to quickly bring up this ft article today, scott, where in china 3/5 of the new coronavirus cases in china show no symptoms. 60% asymptomatic i went back and forth with sam waxel whether that means the virus is mutating to a lis virulent form or whether all along it was 60% and there wasn't enough testing to know that >> yeah, looks like there's a high percentage of patients that

are asymptomatic 60% is the high range. if you look at the french aircraft carrier where it became epidemic, that was around 50%. there was a very good study done in northern italy looking at a town and they found 40% of the spread was asymptomatic. diamond princess was 30% there are studies that have looked at the percentage of asymptomatic spread and you have confined settings and you have seen how much of the infection is asymptomatic versus symptomatic. you've had epidemic and enclosed space. it ranges from 20% to 55% on the high end there's been probably a dozen good studies that's within the range. it's within the range. we're probably diagnosing one in ten to one in 20 it's probably 1/3 of the infections are asymptomatic. we should work on the assumptions when we do our modeling >> becky

>> dr. gottleib, back to remdesivir very quickly. when we had the ceo on i asked them twice keeping in mind the op ed you had written how we need to make sure we have manufacturing for some of these things to make sure that our population can get access to it. asked him twice about whether he's been pressured by any country, either in the manufacturing areas or along the supply chain who has said to him you're going to take care of our population first he didn't really answer the question which to me sounded like a yes, but what do you think? do you think the country that might be pressuring him rhymes with blima or blomerica. >> i think they have a complex manufacturing supply chain that probably takes certain components of this outside of the u.s. they don't have entirely a u.s. supply chain so long as they're dependent on other countries for starting ingredients to that drug most companies are most have starting ingredients

to their drugs that come from that including china they have to make sure they supply the markets i think there's going to be enough doses heading into the fall unless we have a major epidemic if we have something on the proportion of outbreaks, large outbreaks in american cities or even something approximating what we've just gone through, i think we're going to have hundreds of thousands of doses that we would need getting close to millions of doses initially they were talking about having a million doses by the end of the year. now they're talking about having multiples of millions. they can compress the supply chain in the manufacturing cycle. if you get it down to five days from ten which i think you can, that's going to stretch their supply chain even further. i think it's going to be there the other thing you'll see is other companiesstep in to star helping them manufacture this. i think gilead is going to get assistance from other biopharmaceutical companies to look at different components both domestically and abroad

>> hey, dr. gottleib i want to ask you about something completely different which is a report that came out yesterday which is that in switzerland, swiss officials are telling people that young children under the age of 10 can and should or are able to hug their grandparents what did you make of this report did you see this >> i didn't see that particular report there was a study that came out about two or three days ago that seemed to suggest that children both aren't getting infected and aren't passing on the virus. there was one study, some limitations to t. there were other studies that showed the opposite i think this is very inconclusive i have a hard time believing in the absence of really objective data that kids aren't vectors for this i happen to think they're getting infected, they're getting subclinical symptoms

that could be because i have three young kids who constantly get me sick so i'm biased in my analysis i believe that the kids are vectors here until you have really objecttive evidence proving that they're not, it's going to take studies where you are actually evaluating children, swabbing them at large scale to see if it's circulating among kids, those are going to be hard to do until we have that kind of really objective data, i think we should work on the assumption that the kids are probably vectors for the virus and getting colonized with it. we've seen kids getting sick we've seen autoimmune reactions from covid-19. some unusual types of illness. we know kids can get sick from this, just at a much, much smaller proportion than what we're seeing in adults >> hey, scott, do you have an opinion on the way to approach a vaccine? and have you looked into the different platforms enough of

let's say oxford university versus pfizer versus moderna have you looked into it enough to form an opinion on which technique is going to bear the most fruit and easiest to manufacture and quickest to prove efficacy do you know? >> well, i don't think anyone knows right now. oxford is a similar platform to what j&j is doing. there are a couple of companies including pfizer doing mrna. some companies are using traditional approaches, flu block, like sanofi merck seems to be doing something off of the ebola platform there are multiple platforms in development. i think what's going to end up happening is probably more than one is going to make it over the finish line. you'll have some heterogeneity and some will have different

attributes to make them successful we need more than one manufacturer if we only have one manufacturer, we will be severely supply strained i like the fact that there's multiple approaches underway gives us multiple shots on goal. we don't know what's going to be the most effective vaccine, what's going to provide the most immunity having all of these approaches underbe way i think is very good for development and very good for sharing risks. >> dr. gottleib, thanks once again for your quick analysis and joining us today thanks coming up, we're going to go inside big quarterly reports from apple and amazon. both stocks under pressure in the premarket. then dallas mavericks owner mark cuban talks about businesses reopening in texas we'll be right back. life isn't a straight line.

and sometimes, you can find yourself heading in a new direction. but when you're with fidelity, a partner who makes sure every step is clear, there's nothing to stop you from moving forward. confident financial plans, calming financial plans, complete financial plans. they're all possible with a cfp® professional. find yours at letsmakeaplan.org.

they're all possible with a cfp® professional. and... l(music fades in). hey! -hi! ♪ ♪ ♪ ♪

welcome back to "squawk box. dow looks like it would open down 464 points right now. s&p 500 looking to open down 63 points the nasdaq looking to open down 223 points on the backs of reports from apple and amazon last night becky? >> all right, andrew thanks let's get to one of the biggest reports of earnings season cnbc's josh lip ton joins us live with all of the details on apple's latest quarter josh, good morning >> so, becky, i got the chance to catch up with apple ceo tim cook i asked him about iphone demand in china such an important part for them. can we use china as a leading

indicator for other markets. tim cook saying there was a significant, steep falloff in february that began to recover some m march and we've seen further recovery in april. so it leaves us room for optimism it's hard to tell if that's a leading indicator, was his point. there are differences. the u.s. has had a bold stimulus program and i think that will help i'm optimistic in the pace of recovery in the united states. i asked cook about that work from home trend. obviously millions more people working, learning, playing from home how does that really impact demand for apple products. cook telling us it's clearly helping the ipad and the mac for that reason we envision both of those to have improving year over year performances in this current quarter. if you look at apple tv+, as an example, we've seen a significant uptick in the number of people viewing content as well as engagement with content.

i did ask cook about those stores when will more reopen around the world. cook saying, listen, more country by country and county by county he thought the first store in the u.s. could open by mid may we'll have to have a much reduced number of people in the store so what we envision is a store having a certain capacity to it and we'll gate the number of people in that store to that number guys, back to you. >> okay. josh, thanks so much joining us right now to continue the conversation about apple is lams moan. he reiterated his buy rating i want to bring in mitchell green, founding and managing partner of lead edge capital good morning to both of you. i don't know how much time you spent looking at the numbers so much as the tone and the words of tim cook as to what the

future may look like what were you focused on >> yeah, thanks, andrew. thanks for having me good morning >> i was really focused on understanding if management thought there was enough visibility in the future and being able to maintain so far. we walked away with the impression, yes, things might be very marginally delayed. we're holding up extremely well with only possibly 2% down for this pandemic for revenues in the first half of calendar year '20. it's amazing considering there's so much hard work in the business secondarily, i think the fact that they did not have eligibility. the company went out of its way to provide a lot of visibility on every product, on services with a lot more detail than they normally do. so i think that this was a

quarter that apple just did not want to die because there is a black swan issue the last quarter after reporting it indecember and i think they don't want to be easy about that hedging their bets but i don't read it as anything that is impacting the business from a secular perspective. the multiple moves up relatively quickly. >> mitchell, does that make sense to you >> yeah. i would agree with that. look, andrew, apple is not a name we follow as closely because we follow more elite commerce, software stock, but it's an incredible company the demand for their devices is going through the roof, as you know >> right mitchell, what did you make of amazon's numbers but also its decision to take this $4 billion in profit that it would normally make and say it's just plowing it straight back into the

business >> look, the top line numbers for amazon are incredible. 1,000 basis point improvement. 1,000 basis points better growth in the online retail 800 basis points for third party. aws is growing awesome amazon is riding two big waves this is going to put it in the turbo charge mode. and then just the movement to cloud which we're in the early innings of i think it's smart what he's doing. the reality is the stock is where it was two days ago. it hit all-time highs yesterday. they're making absolutely the right -- >> what do you think the stock is right >> what was that a lot higher than it is today.

3,000 bucks a share. >> 3,000 is that a year from now, two years from now >> i think within 12 months. that doesn't mean it's not going to -- for the next 12, 15 monthmonths but i think if you look at it, two to three -- >> wamsi -- >> i was going to say if you look at it over the next three to four years, i think the stock can double >> wamsi, you know, that's a remarkable thing do you think the apple stock could double >> well, look, i mean, andrew, there is a stock here that we're talking about that has gotten a trillion in market cap when you look at the sheer scale of it, it will be contingent on how a lot of other stocks do where is that money really going

to come from apple already has soaked up a lot of capital from a lot of other places to say the stock would double is not sort of within our forecast period range it could happen obviously, but at the same time when we look at where numbers are today, we think the numbers could approach between $17 in earnings a share which is where people were for calendar '21 what does that really mean can you put a 22 multiple on a stock like this because earnings are actually holding up tremendously well? sure that would get you close to a $400 stock can you imagine and construct scenarios that are quite bullish. i think the services will have to be a much larger component from where they are today to justify the doubling of the stock. >> wamsi, mitchell, thanks for joining us this morning. >> thanks for having us. >> thank you over to becky. thank you. when we come back, dallas mavericks owner and all around

shark, mark cuban, is going to join us live we'll get his views on the government's second round for small businesses and what he thinks of texas's reopening programs don't forget, the berkshire hathaway meeting tomorrow. you can email any questions you have to berkshirequestions @cnbc.com we'll ask questions of him tomorrow tune in to "squawk box" at 6 a.m. for an in depth look. yahoo! will be streaming that 'll ve lsaturday wehaots of highlights on monday morning "squawk box" will be right back. there's tv, and then there's

the best entertainment experience. xfinity x1. que welcome back, everybody. joining us is mark cuban he's the owner of the nba's dallas mavericks he's chairman of axs tv.

mark, it's great to be talking to you today what do you think about how texas is going about this at this point how are you feeling? >> you know what, i don't feel bad about it and i'll tell you why. we've had good success with pick up and delivery for restaurants. the governor expanded it to any business, that's a good thing. that's more of an extension than an opening program on the second part of that, he said you couldn't open up a business and open it up for more than 25% of your capacity, which really for most small businesses means you're probably notgoing to open it up at all what we're seeing is a small subset of businesses making themselves available to the public that will be some good knowledge for us and we'll see what happens. >> you're right in thinking that a lot of businesses won't open if they can have 25% capacity. some restaurants said please don't allow us to open up for eat-in dining because it means we have to hire more people and being dine-in will only take the

money we're getting now from the people who are taking out. what do you think? who is going to open up? >> you're right. there are a lot of problems associated with it this is more for perception than reality in terms of trying to create the perception you're opening up when you're not really because there's a lot of downstream problems for small businesses one, if you're going to bring back your employees, then they have to come back. they can't remain on unemployment and particularly for tip-based employees, unless the employer is going to guarantee them a much higher rate because you'll have diminished number of customers, then they're not going to want to come back to work they'll want to stay on unemployment that creates one problem if they do come back to work because you feel you can make the numbers work, depending on where your employees live, they may have to take public transportation in dallas, that could be the bus system, that could be the rail system now you're adding a big load onto the rail system and you're increasing their risk of

catching covid which is not going to benefit your business if that happens. then there's the cost of trying to make sure that you can get your business open just to keep it safe. do you have to deal with your hvac system, sterilization, disposal of masks and other things what about all of these downstream issues that haven't been addressed and small businesses haven't been provided the support they need. i think it's more show than go but let's see what happens. >> mark, let's talk about the second wave of loans that are going to be available for small businesses i think all of us have seen an evolution in our views of what should happen with this. everybody's got their own nuance i think in the beginning you were very adamant this should be going to small businesses and not large businesses a more nuanced take. the companies you invest in shouldn't be penalized for having a wealthy investors they should be allowed to go to the tranche and say they're a

small business and qualify everybody has their own perspective on this. it does get more complicated as we follow the money and see where it's going. >> it depends. with the affiliate roles with the small business administration are complex and confusing. what i was trying to do with the sba and treasury is get clarification. for instance, i have shark tank companies i'm not involved in the day-to-day activities but because i have 20% of them, let's just say i gave them $25,000 for 20% of the company, they've been precluded in some cases from being able to apply and so then the natural response is, well, you've got mark cuban as an investor try to give them money is either going to dilute them, becomes a loan or if i want to grant it to them, then i actually have to pay taxes on that as a gift. i have to pay the gift taxes for it that creates its own set of problems again, it's a set of

circumstances where i think it hasn't been all the way thought through. that's not a surprise given how it has been done i was trying to push through clarification more than anything else >> mark, i was curious about what you thought about how some of these ppp loans are going out. one of the things that's been quite surprising is in states that have been the hardest hit, obviously am' a new yorker, but new york, new jersey, the tri state area obviously, some of these -- the percentage of ppp loans that are being approved are something on the order of about 25%. i mentioned yesterday nebraska is getting, you know, 90% or 80% of their loans approved. you're looking at 70% rates in montana, minnesota, wisconsin. >> that's exactly what you should expect. that's what you expect the way the program was designed because what happens is the banks are the ones doing the approvals by definition your banks in new york and any dense area with a lot of businesses are going to have more customers, more

applications and it's going to be more difficult for them to get these loans, whereas, in smaller communities it will be easier for them to process the loans and you'll get more approvals. what i've suggested to everybody that will listen is if you're a small business and you happen to bank at a big bank, it's okay to go find a small community bank and apply there as well. there's no rules against having multiple applications. you just can't take multiple loans. if you are in new york city and there's a smallback with a hism bank with a high approval rate, you already down on the list, apply as many different places as you can that's part one. part two is there's still a lot of confusion for independent contractors. that's where the real problems occur. for independent contractors you have to go and show your 2018 and 2019 tax returns i think it is and that creates a lot of

problems because the independent contractors who are not making money right now have been given the ability, like all of us, to defer filing our 2019 tax returns. so a lot of them are in that catch 22 where you need to have a 2019 tax return. if you haven't filed it yet you don't have t then you're part of that race to get funded. it's created a lot of unintended consequences again, now with the second tranche, give that 2019 payroll tax -- 2019 income tax filed -- filled out it doesn't even have to be filed, go to a bank. all of these complications, you have to keep applying and find the right bank to help you. >> mark, do you think it's the bank's fault or how the sba is deciding which banks to -- >> no, it's not anybody's fault. yeah, it's not anybody's fault. >> i've actually heard that some of the big banks have loans that are waiting to be processed that

have been sitting there. >> there's a couple things there. with the second tranche the sba wants big banks to be able to throw hundreds of thousands of loans into the system so they put some governors into the program where i think they can only file 350 loans at a time in order to give some of the smaller banks a chance to get in the cue, right the big banks have automated the process and were just sending a boatload of applications so they wanted to make it so smaller banks could have smaller customers. that was good in some respects for smaller banks but if you were a couple at a larger bank you were kind of stuck because at 350 at a time, they may not get to you ever. law of unintended consequences the sba was trying to make it fair, but unfortunately they made it more difficult and put large banks in a hard position it wasn't anybody's fault, they were just trying to find a solution and they didn't you know, i recommended to them,

i recommended to treasury that it should be a lottery so that whenever anybody applied, it goes into a central repository treasury treasury randomly picks 50,000 loans to approve they see what the total is and, you know, however much money left they have, they go to the next 50,000 until it's gone. that's the only way to be objective and fair trying to be subjective saying you have more need than another is almost impossible >> thank you that's thought full. mark, appreciate your time good to see you. >> appreciate it thanks, becky. thanks, andrew. >> thanks. coming up when we return, we're going to check in with jim cramer, head of may's first trading day. find out whether we should sell in may, go away. talk markets with john rogers. we are in the red this morning dow down about 457 points. nasdaq off 208 s&p 500 looking to open down 61

points stay tuned, you're watching "squawk" on cnbc every financial plan needs a cfp® professional --

confident financial plans, calming financial plans, complete financial plans. they're all possible with a cfp® professional. find yours at letsmakeaplan.org.

welcome back to "squawk box" this morning the dow just finished out. gains since 1987 the s&p posted its third biggetbig et gest monthly gain. we are joined by john rogers it's great to see you. i don't know if you saw the top of the show, at 6:00 a.m i know you're in chicago it may be early. we had a big debate, we made a bet about what may was going to look like. the question is do you want to sell in may and go away? what would happen to the market at the end of this month given that so many people think that the market is overvalued that seems to be the prevailing

thought. every time there's a prevailing thought, the market seems to almost always work against you >> well, you know, i'm convinced of the markets are still reasonably valued. so much of the markets are smaller, mid-sized companies that have been devastated this year the markets have been propped up by the big f.a.n.g. five stocks. so i think when you look at the overall market, there's a lot of bargains, a lot of opportunity we're out there buying >> so you're out there buying. you think -- if you were going to take the bet on where the market was at the end of may with us, i get doughnuts, joe gets tacos, and becky gets a hypoallergenic dog potentially what's your gamble >> i think -- i wouldn't be surprised to see the market up -- we're long, long-term investors. you never know month to month.

i do tend to think as we move into may and we see the states opening up slowly but surely, and the death toll, the tragedy starting to unfold in a way that will be much more positive, there will be a lot less deaths, a lot less cases, that will start to rebuild confidence in america with our consumers, and the overall economic system. >> so you were talking about how you saw opportunity right now. what areas are you looking at? >> we're loving to look at the areas that have really gotten crushed because people are afraid that people will not come back to certain sectors again. so we like some of the places like vail. we think people will ski again we've been buying madison square garden entertainment pe people, we think, will go back to the garden one day and watch

concerts, basketball and hockey and they own lots and lots of land there around the garden it's a great real estate play, too. our favorite name is envista it's a cheap stock most dental offices have been closed, but we'll have to maintain our teeth, it will be something that's really important as people come out of this crisis. probably people need more dental services because they have been delaying so they will be well positioned. >> given that you're going to travel spaces like vail and other places like that, what do you make of retail >> we've not been investing in retail for a long time we're very cautious. we think that world has changed so dramatically. you can get whatever you need from amazon or direct from the product manufacturers.

i'm on the board of nike, they have great website, you can get the greatest running shoes that way. so i think retail is an area that we'll be very, very cautious about >> another question is what do you make of tech right now as you said, the market is being propped up in large part by a handful of tech names. >> i think right now when ever you see a handful of names dominate the s&p the way the f.a.n.g. stocks have, it's usually a sign that the markets are going to change dramatically what works coming out of this environment we think will be different than what worked in the last environment i was talking abouted ethis wit the ceo of lazard, and they said when you come out of this, it's a different type of environment. active management is going to work again just buying the stocks that were up in the past will not be the play for the future.

>> john rogers, always great to get your insights and perspective. stay safe and healthy. >> thank you let's get to cnbc headquarters, i wish we had more time, jim. i don't know where you want to start. i was thinking of the overall sort of conversation about how the drug industry is viewed. my view is if they get us out of this with innovation and everything else, we'll understand you need to invest long-term in drugs to get them, and they won't be on the losing end of the pr battles. >> can you and i go after the people who criticize thin industry >> that's what i was sort of thinking of. >> they're sacrificing profits for lives. they've always been viewed as capitalists. that over. that dialogue if it comes back, we'll have to punch them in the nose that's figurative, not literal >> that was my take on this. we've seen what happens if you don't fund your drug industry

around the world it's the reason -- the one thing, jim, in the past they have extended patents with some joke xl, and then you see it on tv, that's the way they get the patent protection. they've abused that. but overall if you can get a drug instead of going to the hospital, it's so much better. isn't it >> these companies -- that interview was so unbelievable. what was he really saying? listen, we'll lose some money, you know why we're drug companies, that's what we do >> right >> that was the narrative. >> i tire of the people who criticize this industry. yes, mylan had some epipen the this is about a pandemic that's 100 million lives >> how about sell in may you want in on this bet? it's impossible -- >> you had the best april since '87. >> that's what i mean. reversion of the mean. >> exactly can i say your interviews this morning set the whole tone anything else you read in the papers or what anyone is saying,

forget about it. you got all the stuff. the combination of gottlieb a day, basically told you we made our first inroad maybe we have our first part of the cocktail those who thought we should trust the chinese study, i don't know if you were reading the chinese study, i don't think you would give anyone this drug. how would they be doing if they didn't have it >> last time i believe them. didn't believe a whole lot coming out of them >> i like the drug industry. >> we'll see you in a few minutes. hopefully you continue on along that line. don't miss larry kudlow first on cnbc interview, national economic council director larry lo that's at the top of the hour stay tuned "squawk box" is coming right back these days staying connected is more important than ever.

so we're working 24/7 to maintain a reliable network, to meet your growing internet needs. we're helping customers who are experiencing financial difficulties stay connected. we're increasing internet speeds for low income families in our internet essentials program. and delivering self-install kits to your door. nos comprometemos a mantenerte conectado. we're committed to keeping you connected. for more information on how you can stay connected, visit xfinity.com/prepare.

let's take a fanl loinal lot the markets. dow down by 447 points wti, oil prices up sharply we spoke with chevron's ceo mike worth later on today he said he thinks demand for oil has bottomed wti trading up by almost 7%. we'll be back on monday with thoughts from warren buffett right now it's time for "squawk on the street. good friday morning. welcome to "squawk on the street." i'm carl quintanilla with jim cramer, david faber live from specific locations futures are weak on this first day of may as we watch earnings out of apple, amazon, exxon, chevron. got an increase in u.s./china trade tensions as well with the president threatening additional tariffs. oil up 6%. all kinds of reasons given for